Abstract 88P
Background
Poly(ADP-ribose) polymerase (PARP) plays a crucial role in DNA repair pathways. PARP trapping induced by PARP inhibitors (iPARPs) leads to replication fork collapse, resulting in clinically relevant cytotoxicity. Therefore, the aim of this study is to describe the potential impact of PARP mutations on interaction with iPARPs.
Methods
The study design involved molecular docking simulations between iPARPs (olaparib, rucaparib, and niraparib) and PARP using Autodock Vina. We reviewed PARP mutations in the COSMIC database and predicted the pathogenicity of mutations near the interaction residues of PARP with the identified iPARPs from the molecular docking.
Results
The amino acids may be related to the interaction of olaparib (Lysine703, Arginine704, Glutamate642, Leucine641, Alanine555, Tryptophan626), niraparib (Alanine555, Tryptophan626, Lysine551, Valine552, Serine554, Glycine530), and rucaparib (Arg878, Aspartate770, Aspartate766, Glutamine759, Glycine888, Tyrosine907) with PARP. In the database, 867 mutations for PARP1 are reported. Among the amino acid residues identified for interaction with olaparib, only the mutation at amino acid 555 (Alanine555Valine) was reported. Regarding niraparib binding sites, mutations were found in amino acids 551 (Lysine551Arginine) and 626 (Tryptophan626Leucine). For Rucaparib, mutations were identified in amino acids 759 (Glutamine759Proline), 766 (Aspartic Acid766Asparagine), 878 (Arginine878Tryptophan), and 888 (Glycine888Aspartic Acid).
Conclusions
Amino acids and their mutations that could be involved in the interaction of olaparib, rucaparib, and niraparib with PARP were identified. Recognizing fewer mutations interacting with olaparib and a greater number interacting with the other PARP inhibitors, olaparib has demonstrated superiority in patients with recurrent disease and BRCA mutations sensitive to platinum. However, prospective studies comparing different PARP inhibitors are needed. Our findings highlight the importance of PARP1 interaction with inhibitors in conferring intrinsic resistance with this new therapy. Further study and supplementation of PARP1 mutation databases are necessary to understand their impact on functionality and determine clinical implications.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
J.F. Diaz Acosta.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
174P - Human adipose stem cells transfer their mitochondria to breast cancer patient derived organoids increasing drug resistance
Presenter: Martina Marigliano
Session: Cocktail & Poster Display session
Resources:
Abstract
175P - Differential impact of increased neoantigen load on PD-L1 positive immune cell infiltrations in comparison to PD-L1 expression on tumor cells
Presenter: Ashok Kumar Vaid
Session: Cocktail & Poster Display session
Resources:
Abstract
176P - Patient race is a determinant of the impact of Y chromosome loss on survival
Presenter: Suhyeon Choi
Session: Cocktail & Poster Display session
Resources:
Abstract
178P - Clinical correlates and impact of ctDNA levels on detecting distinct genomic alteration in patients with metastatic colorectal cancer
Presenter: Luca Boscolo Bielo
Session: Cocktail & Poster Display session
Resources:
Abstract
179P - Identification of guanine-quadruplex forming DNA aptamer: A promising therapeutic strategy for EGFR overexpressed non-small cell lung cancer
Presenter: Deepa Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
180P - Unravelling drug resistance in high-grade serous ovarian cancer through clonal dynamics and single-cell heterogeneity analysis
Presenter: Alvaro Ingles Russo Garces
Session: Cocktail & Poster Display session
Resources:
Abstract
181P - Establishment of primary prostate cancer patient-derived organoids to assess PARP inhibitors antitumor activity beyond synthetic lethality
Presenter: Tatiana P. Grazioso
Session: Cocktail & Poster Display session
Resources:
Abstract
182P - METHRO: Multicentric study of risk of thrombosis in patients with NSCLC harboring a METexon 14 skipping mutation
Presenter: Maria Virginia Sanchez Becerra
Session: Cocktail & Poster Display session
Resources:
Abstract
183P - SomaVar: A web application for somatic variant storage, annotation and classification
Presenter: Sorin Armeanu-Ebinger
Session: Cocktail & Poster Display session
Resources:
Abstract